Currently out of the existing stock ratings of Brian Cheng, 55 are a BUY (77.46%), 13 are a HOLD (18.31%), 3 are a SELL (4.23%).

Brian Cheng

Work Performance Price Targets & Ratings Chart

Analyst Brian Cheng, currently employed at JPMORGAN, carries an average stock price target met ratio of 44.47% that have a potential upside of 17.06% achieved within 73 days.

Brian Cheng’s has documented 138 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ROIV, Roivant Sciences Ltd at 18-Sep-2025.

Wall Street Analyst Brian Cheng

Analyst best performing recommendations are on CRGX (CARGO THERAPEUTICS, COMMON STOCK).
The best stock recommendation documented was for PTGX (PROTAGONIST THERAPEUTICS) at 3/4/2025. The price target of $57 was fulfilled within 7 days with a profit of $18.34 (47.44%) receiving and performance score of 67.77.

Average potential price target upside

of $15.72 (15.48%) on BPMC (BLUEPRINT MEDICINES CORP).
of $12.71 (44.66%) on PTGX (PROTAGONIST THERAPEUTICS).
of $12.41 (54.76%) on SRRA (SIERRA ONCOLOGY).

ARCT Arcturus Therapeutics Holdings PSTX Poseida Therapeutics ADCT ADC Therapeutics SA IMNM Immunome SRRA Sierra Oncology GOSS Gossamer Bio APLS Apellis Pharmaceuticals NTLA Intellia Therapeutics ROIV Roivant Sciences Ltd XNCR Xencor ACET Adicet Bio BCAB Bioatla ALLO Allogene Therapeutics MRSN Mersana Therapeutics PTGX Protagonist Therapeutics ZYME Zymeworks Common Stock BPMC Blueprint Medicines Corp EDIT Editas Medicine IMVT Immunovant CRGX CARGO Therapeutics, Common Stock KYTX Kyverna Therapeutics, Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Yigal Nochomovitz (CITI)